Cationic emulsions improves the delivery of oligonucleotides to leukemic P388/ADR cells in ascite

Journal of Controlled Release

Volumn 89, Issue 3, 2003, Pages 473-482

  Teixeira, H ^a,b   Dubernet, C ^a   Chacun, H ^a   Rabinovich, L ^a,c   Boutet, V ^d   Deverre, J R ^d   Benita, S ^c,e   Couvreur, P ^a  

^a UNIV PARIS SUD   (France)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Novagali Pharma   (France)

^d Institut National de la Recherche Agronomique   (France)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Leukemic P388 ADR cells; O W cationic emulsions; Oligonucleotides

Indexed keywords

BIOLOGICAL ORGANS; BLOOD; CELLS; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; FLUIDIZATION; LIPIDS; ONCOLOGY; RADIOACTIVITY; SCINTILLATION COUNTERS; TUMORS;

OLIGONUCLEOTIDES;

EMULSIONS;

ALPHA TOCOPHEROL; CATION; LIPID; LIPOID E 80; MEDIUM CHAIN TRIACYLGLYCEROL; OLIGONUCLEOTIDE; PHOSPHATIDYLCHOLINE; POLOXAMER;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; ASCITES CELL; BLOOD SAMPLING; CANCER CELL; CELL STRAIN; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; FLUIDIZATION; IN VIVO STUDY; INOCULATION; LEUKEMIA CELL; LIQUID SCINTILLATION COUNTING; MODEL; MOUSE; NONHUMAN; ORGAN; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0038402547     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00101-9     Document Type: Article

References (14)

1. B.P. Monia, Antisense as a novel therapy for cancer, in: P. Couvreur, C. Malvy (Eds.), Pharmaceutical Aspects of Oligonucleotides, Taylor and Francis, London, 2000, pp. 243-260.
2. Eder P.S., DeVine R.J., Dagle J.M., Walder J.A. Substrate specificity and kinetics of degradation of antisense oligonucleotides by 3′ exonuclease in plasma. Antisense Res. Dev. 1:1991;141-151.
3. Zelphati O., Szoka F.C. Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm. Res. 13:1996;1367-1372.
4. Srinivasan S.K., Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J. Lab Anal. 9:1995;129-137.
5. Rojanasakul Y. Antisense oligonucleotide therapeutics: drug delivery and targeting. Adv. Drug Deliv. Rev. 18:1996;115-131.
6. Brazeau G., Attia S., Poxon S., Hugues J. In vitro myotoxicity of selected cationic macromolecules used in non-viral gene delivery. Pharm. Res. 15:1998;680-684.
7. Bennett C.F., Chiang M.Y., Chan H., Schoemaker J.E., Mirabelli C.K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41:1992;1023-1033.
8. Saijo Y., Perlaky L., Wang H., Bush H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6:1994;243-249.
9. Klang S., Frucht-Pery J., Hoffman A., Benita S. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J. Pharm. Pharmacol. 46:1994;986-993.
10. Teixeira H., Dubernet C., Puisieux F., Benita S., Couvreur P. Submicron cationic emulsions as a new delivery system of oligonucleotides. Pharm. Res. 16:1999;30-36.
11. Teixeira H., Dubernet C., Rosilio V., Laigle A., Deverre J.R., Scherman D., et al. Factors influencing the oligonucleotides release from O/W submicron cationic emulsions. J. Controlled Release. 70:2001;243-255.
12. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., et al. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44:1992;509-517.
13. Tsuchihashi M., Harashima H., Kiwada H. Development of a pharmaco kinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. J Controlled Release. 61:1999;9-19.
14. Litzinger D.C., Brown J.M., Wala I., Kaufman S.A., Van G.Y., Farrell C.L., et al. Fate of cationic liposomes and their complex with oligonucleotide in vivo. Biochim. Biophys. Acta. 1281:1996;139-149.